Novo Nordisk Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 92
NovoEight® is launched in the US, Europe and Japan for the
treatment of people with haemophilia A
Example from Novo Eight®
promotional campaign¹
1 Picture is not intended for promotional purposes
changing
diabetes®
NovoEight® properties and launch performance
Indications:
•
Treatment and prophylaxis of bleeding in patients with
congenital factor VIII deficiency for all age groups²
Key product characteristics:
.
.
Reliability: No inhibitor development in PTPs in one of the
largest pivotal trial programmes of any approved rFVIII
(n=213)2,3
Purity and safety: First rFVIII to use a 20nm filter in its
purification process4
• Portability: Room temperature stability with storage at 30
degrees celsius²
Launch status:
•
NovoEight® is available in the US, EU, Japan and 17
additional countries
2 NovoEight® Summary of Product Characteristics. 3 Iorio A et al., Blood 2012; 120(4):
720 727. NovoEight® Prescribing Information
PTP: Previously treated patient
novo nordiskView entire presentation